Heat Biologics Profit Margin

The latest profit margin for HTBX is -702.87% as of September 2025. That compares with -4348.21% in the prior-year period — up 83.8% year over year. That is below the Healthcare sector average of 17.63%. Investors often review this figure alongside Heat Biologics's historical trend and sector peers before judging valuation or financial health.

Over the past year, HTBX's profit margin moved from -4348.21% to -702.87% — a 83.8% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Heat Biologics's valuation or profitability profile.

Against Healthcare companies, HTBX currently prints -702.87% for profit margin, while the sector average sits near 17.63%. That is roughly 4087.1% below the sector mean. Large gaps often invite a closer look at Heat Biologics's growth, margins, and balance sheet.

Profit Margin shows how effectively Heat Biologics converts resources into returns. At -702.87%, HTBX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4348.21% in the prior-year period — up 83.8% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting HTBX's profit margin (-702.87%), review year-over-year change from -4348.21%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.